Cargando…

A Physiologically Based Pharmacokinetic Model to Predict Potential Drug–Drug Interactions and Inform Dosing of Acumapimod, an Oral p38 MAPK Inhibitor

Acumapimod, an investigational oral p38 mitogen‐activated protein kinase inhibitor for treatment during severe acute exacerbations of chronic obstructive pulmonary disease, is metabolized primarily by cytochrome P450 3A4 (CYP3A4) and is a P‐glycoprotein (P‐gp) substrate. Concerns about drug–drug int...

Descripción completa

Detalles Bibliográficos
Autores principales:	Agyemang, Alex, Farrell, Colm, Moore, William, Parkin, Jacqueline
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7825188/ https://www.ncbi.nlm.nih.gov/pubmed/33107218 http://dx.doi.org/10.1002/psp4.12565

Ejemplares similares

Is p38 MAPK Associated to Drugs of Abuse-Induced Abnormal Behaviors?
por: El Rawas, Rana, et al.
Publicado: (2020)

Physiologically‐Based Pharmacokinetic Model‐Informed Drug Development for Fenebrutinib: Understanding Complex Drug‐Drug Interactions
por: Chen, Yuan, et al.
Publicado: (2020)

Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug‐Drug Interactions and Pediatric Dose Regimens
por: Cohen‐Rabbie, Sarit, et al.
Publicado: (2021)

Physiologically based pharmacokinetic modeling to assess metabolic drug–drug interaction risks and inform the drug label for fedratinib
por: Wu, Fan, et al.
Publicado: (2020)

Predicting Oral Drug Absorption: Mini Review on Physiologically-Based Pharmacokinetic Models
por: Lin, Louis, et al.
Publicado: (2017)

Characterizing Pharmacokinetics in Children With Obesity—Physiological, Drug, Patient, and Methodological Considerations
por: Gerhart, Jacqueline G., et al.
Publicado: (2022)

Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz
por: Siccardi, Marco, et al.
Publicado: (2013)

Development and Evaluation of a Physiologically Based Pharmacokinetic Drug-Disease Model of Propranolol for Suggesting Model Informed Dosing in Liver Cirrhosis Patients
por: Kalam, Muhammad Nasir, et al.
Publicado: (2021)

p38γ MAPK Inflammatory and Metabolic Signaling in Physiology and Disease
por: Qi, Xiao-Mei, et al.
Publicado: (2023)

Physiologically Based Pharmacokinetic Modelling to Identify Physiological and Drug Parameters Driving Pharmacokinetics in Obese Individuals
por: Berton, Mattia, et al.
Publicado: (2022)

First dose in children: physiological insights into pharmacokinetic scaling approaches and their implications in paediatric drug development
por: Strougo, Ashley, et al.
Publicado: (2012)

Drug Dosing in Pregnant Women: Challenges and Opportunities in Using Physiologically Based Pharmacokinetic Modeling and Simulations
por: Ke, Alice Ban, et al.
Publicado: (2018)

Napabucasin Drug‐Drug Interaction Potential, Safety, Tolerability, and Pharmacokinetics Following Oral Dosing in Healthy Adult Volunteers
por: Dai, Xiaoshu, et al.
Publicado: (2021)

Quercetin Suppresses Drug-Resistant Spheres via the p38 MAPK–Hsp27 Apoptotic Pathway in Oral Cancer Cells
por: Chen, Su-Feng, et al.
Publicado: (2012)

Comprehensive Physiologically Based Pharmacokinetic Model to Assess Drug–Drug Interactions of Phenytoin
por: Rodriguez-Vera, Leyanis, et al.
Publicado: (2023)

Application of Physiologically Based Pharmacokinetic Modeling to Evaluate the Drug–Drug and Drug–Disease Interactions of Apatinib
por: Liu, Hongrui, et al.
Publicado: (2021)

Pharmacokinetic relevance of glomerular hyperfiltration for drug dosing
por: Zoccali, Carmine, et al.
Publicado: (2023)

Impact of Physiologically Based Pharmacokinetics, Population Pharmacokinetics and Pharmacokinetics/Pharmacodynamics in the Development of Antibody‐Drug Conjugates
por: Li, Chunze, et al.
Publicado: (2020)

Physiologically Based Pharmacokinetic Modeling for Olaparib Dosing Recommendations: Bridging Formulations, Drug Interactions, and Patient Populations
por: Pilla Reddy, Venkatesh, et al.
Publicado: (2018)

The Role of Transporters in the Pharmacokinetics of Orally Administered Drugs
por: Shugarts, Sarah, et al.
Publicado: (2009)

Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug Exposure and Support Dosing Recommendations for Potential Drug‐Drug Interactions or in Special Populations: An Example Using Tofacitinib
por: Tse, Susanna, et al.
Publicado: (2020)

Predictive Performance of Physiologically Based Pharmacokinetic Models for the Effect of Food on Oral Drug Absorption: Current Status
por: Li, Mengyao, et al.
Publicado: (2017)

Food Effects on Oral Drug Absorption: Application of Physiologically-Based Pharmacokinetic Modeling as a Predictive Tool
por: Cheng, Lisa, et al.
Publicado: (2020)

Physiologically Based Pharmacokinetic Models in the Prediction of Oral Drug Exposure Over the Entire Pediatric Age Range—Sotalol as a Model Drug
por: Khalil, Feras, et al.
Publicado: (2014)

Use of physiologically‐based pharmacokinetic modeling to inform dosing of the opioid analgesics fentanyl and methadone in children with obesity
por: Gerhart, Jacqueline G., et al.
Publicado: (2022)

Pharmacokinetics and Dialyzability of a Single Oral Dose of Amenamevir, an Anti-Herpes Drug, in Hemodialysis Patients
por: Tsuruoka, Shuichi, et al.
Publicado: (2020)

Simulation and Prediction of the Drug‐Drug Interaction Potential of Naloxegol by Physiologically Based Pharmacokinetic Modeling
por: Zhou, D, et al.
Publicado: (2016)

Physiologically‐Based Pharmacokinetic Modeling to Support the Clinical Management of Drug–Drug Interactions With Bictegravir
por: Stader, Felix, et al.
Publicado: (2021)

Physiologically Based Pharmacokinetic Modeling of Rosuvastatin to Predict Transporter-Mediated Drug-Drug Interactions
por: Hanke, Nina, et al.
Publicado: (2021)

Evaluation of drug–drug interaction potential for pemigatinib using physiologically based pharmacokinetic modeling
por: Ji, Tao, et al.
Publicado: (2022)

Physiologically Based Pharmacokinetic Modeling and Simulation in Pediatric Drug Development
por: Maharaj, A R, et al.
Publicado: (2014)

A Physiology-Based Pharmacokinetic Framework to Support Drug Development and Dose Precision During Therapeutic Hypothermia in Neonates
por: Smits, Anne, et al.
Publicado: (2020)

p38 MAPK in MDS
por: Gañán‐Gómez, Irene, et al.
Publicado: (2015)

Pharmacokinetics of orally administered single‐dose ponazuril in cats
por: Burlison, Catherine, et al.
Publicado: (2022)

Developing a mechanistic understanding of the nonlinear pharmacokinetics of letermovir and prospective drug interaction with everolimus using physiological‐based pharmacokinetic modeling
por: Menzel, Karsten, et al.
Publicado: (2023)

Evaluating the Role of Solubility in Oral Absorption of Poorly Water‐Soluble Drugs Using Physiologically‐Based Pharmacokinetic Modeling
por: Fink, Christina, et al.
Publicado: (2019)

Application of physiologically based pharmacokinetic modeling in predicting drug–drug interactions for sarpogrelate hydrochloride in humans
por: Min, Jee Sun, et al.
Publicado: (2016)

Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug–Drug Interaction Between Clopidogrel and Dasabuvir
por: Shebley, M, et al.
Publicado: (2017)

Physiologically Based Pharmacokinetic Models of Probenecid and Furosemide to Predict Transporter Mediated Drug-Drug Interactions
por: Britz, Hannah, et al.
Publicado: (2020)

Prediction of Drug–Drug Interaction Potential of Tegoprazan Using Physiologically Based Pharmacokinetic Modeling and Simulation
por: Yoon, Deok Yong, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_d7heict5l7jhcu862k0n33gds3